Exemestane with ovarian suppression in premenopausal breast cancer
- PMID: 25271610
- DOI: 10.1056/NEJMc1409366
Exemestane with ovarian suppression in premenopausal breast cancer
Comment on
-
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. N Engl J Med. 2014. PMID: 24881463 Free PMC article. Clinical Trial.
-
Exemestane with ovarian suppression in premenopausal breast cancer.N Engl J Med. 2014 Oct 2;371(14):1357. doi: 10.1056/NEJMc1409366. N Engl J Med. 2014. PMID: 25271611 No abstract available.
-
Exemestane with ovarian suppression in premenopausal breast cancer.N Engl J Med. 2014 Oct 2;371(14):1358. doi: 10.1056/NEJMc1409366. N Engl J Med. 2014. PMID: 25271612 No abstract available.
-
Exemestane with ovarian suppression in premenopausal breast cancer.N Engl J Med. 2014 Oct 2;371(14):1358. doi: 10.1056/NEJMc1409366. N Engl J Med. 2014. PMID: 25271613 No abstract available.
Similar articles
-
Exemestane with ovarian suppression in premenopausal breast cancer.N Engl J Med. 2014 Oct 2;371(14):1358. doi: 10.1056/NEJMc1409366. N Engl J Med. 2014. PMID: 25271613 No abstract available.
-
Exemestane with ovarian suppression in premenopausal breast cancer.N Engl J Med. 2014 Oct 2;371(14):1358. doi: 10.1056/NEJMc1409366. N Engl J Med. 2014. PMID: 25271612 No abstract available.
-
Exemestane with ovarian suppression in premenopausal breast cancer.N Engl J Med. 2014 Oct 2;371(14):1357. doi: 10.1056/NEJMc1409366. N Engl J Med. 2014. PMID: 25271611 No abstract available.
-
Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients.Indian J Cancer. 2019 Oct-Dec;56(4):293-296. doi: 10.4103/ijc.IJC_697_18. Indian J Cancer. 2019. PMID: 31607695 Review.
-
Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.Drugs. 2017 Dec;77(18):2037-2048. doi: 10.1007/s40265-017-0849-3. Drugs. 2017. PMID: 29177573 Review.
Cited by
-
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.ESMO Open. 2020 Sep;5(5):e000743. doi: 10.1136/esmoopen-2020-000743. ESMO Open. 2020. PMID: 32893189 Free PMC article.
-
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).Breast Care (Basel). 2019 Oct;14(5):315-324. doi: 10.1159/000502603. Epub 2019 Sep 17. Breast Care (Basel). 2019. PMID: 31798392 Free PMC article. Review.
-
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).Geburtshilfe Frauenheilkd. 2017 Jun;77(6):633-644. doi: 10.1055/s-0043-111601. Epub 2017 Jun 28. Geburtshilfe Frauenheilkd. 2017. PMID: 28769126 Free PMC article.
-
Progress in adjuvant chemotherapy for breast cancer: an overview.BMC Med. 2015 Aug 17;13:195. doi: 10.1186/s12916-015-0439-8. BMC Med. 2015. PMID: 26278220 Free PMC article. Review.
-
Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019).Geburtshilfe Frauenheilkd. 2019 Jun;79(6):591-604. doi: 10.1055/a-0897-6457. Epub 2019 Jun 14. Geburtshilfe Frauenheilkd. 2019. PMID: 31217628 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical